Can Lamictal (lamotrigine) cause tardive dyskinesia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Lamictal (lamotrigine) is not typically associated with causing tardive dyskinesia. Tardive dyskinesia is a movement disorder characterized by involuntary, repetitive movements that most commonly occurs as a side effect of long-term use of antipsychotic medications, particularly first-generation (typical) antipsychotics 1. Lamictal is an anticonvulsant medication primarily used to treat epilepsy and bipolar disorder, and it works through different mechanisms than antipsychotics. It stabilizes neuronal membranes by inhibiting voltage-sensitive sodium channels and reducing the release of excitatory neurotransmitters like glutamate. While Lamictal can cause other side effects such as skin rashes, headaches, dizziness, and coordination problems, it does not typically affect the dopamine pathways in the brain that are implicated in tardive dyskinesia development.

Some key points to consider:

  • Tardive dyskinesia is a major public health concern in the treatment of schizophrenia, with both clinical and medicolegal implications 1.
  • The atypical antipsychotic agents are theoretically less likely than the conventional neuroleptics to cause extrapyramidal side effects, including tardive dyskinesia 1.
  • If you're experiencing abnormal movements while taking Lamictal, it's essential to consult with your healthcare provider promptly as this could be related to another condition or medication interaction rather than tardive dyskinesia specifically from Lamictal.
  • The Abnormal Involuntary Movement Scale (National Institute of Mental Health, 1985) is a useful measure for monitoring tardive dyskinesia, and assessment for dyskinesias should occur at least every 3 to 6 months in patients taking antipsychotic medications 1.

In terms of management, if tardive dyskinesia occurs, the medication should be continued at the current dose only if the patient is in full remission and there is reason to believe that any change in dosage or agent will precipitate a relapse 1. Otherwise, attempts should be made to either lower the dose or switch to another medication, most likely an atypical antipsychotic. However, this is more relevant to antipsychotic medications rather than Lamictal.

From the Research

Tardive Dyskinesia and Lamictal

  • There are no research papers provided that directly address the question of whether Lamictal can cause tardive dyskinesia.
  • However, the provided studies discuss the treatment and management of tardive dyskinesia, which is often associated with the use of antipsychotic medications 2, 3, 4, 5.
  • Tardive dyskinesia is a side effect of dopamine blocking agents, most often antipsychotics, and can be socially and physically disabling 5.
  • Some studies suggest that vitamin E may be effective in reducing the severity of tardive dyskinesia, especially in patients who have had the condition for 5 years or less 2, 3.
  • Other studies discuss the use of vitamin E and C in combination as a potential treatment for tardive dyskinesia in patients with affective disorders 6.
  • It is essential to note that the provided studies do not mention Lamictal as a potential cause of tardive dyskinesia, and therefore, no conclusion can be drawn from the available evidence.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Vitamin E for antipsychotic-induced tardive dyskinesia.

The Cochrane database of systematic reviews, 2018

Research

Tardive dyskinesia: Out of the shadows.

Journal of the neurological sciences, 2018

Research

Tardive dyskinesia: clinical presentation and treatment.

International review of neurobiology, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.